Recently Adopted and Issued Accounting Guidance - Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Other current assets	$ 6,161	$ 5,153
Other assets	1,302	891
Total Assets		344,454
Current pharma contract liability	2,155	1,406
Long-term pharma contract liability	648	283
Deferred income tax liability, net	6,827	6,688
Stockholders' Equity	164,209	171,962
Total Liabilities and Stockholders' Equity	$ 345,783	344,454
As Reported
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Other current assets		4,241
Other assets		689
Total Assets		343,340
Current pharma contract liability		0
Long-term pharma contract liability		0
Deferred income tax liability, net		6,307
Stockholders' Equity		172,918
Total Liabilities and Stockholders' Equity		343,340
Impact of Adoption | Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Other current assets		912
Other assets		202
Total Assets		1,114
Current pharma contract liability		1,406
Long-term pharma contract liability		283
Deferred income tax liability, net		381
Stockholders' Equity		(956)
Total Liabilities and Stockholders' Equity		$ 1,114